ALNYLAM PHARMACEUTICALS ($ALNY) posted quarterly earnings results on Thursday, October 30th. The company reported earnings of $2.90 per share, beating estimates of $0.76 by $2.14. The company also reported revenue of $1,249,030,000, beating estimates of $997,349,880 by $251,680,120.
You can see Quiver Quantitative's $ALNY stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ALNYLAM PHARMACEUTICALS Insider Trading Activity
ALNYLAM PHARMACEUTICALS insiders have traded $ALNY stock on the open market 162 times in the past 6 months. Of those trades, 0 have been purchases and 162 have been sales.
Here’s a breakdown of recent trading of $ALNY stock by insiders over the last 6 months:
- YVONNE GREENSTREET (Chief Executive Officer) has made 0 purchases and 23 sales selling 66,840 shares for an estimated $22,733,214.
- DENNIS A AUSIELLO has made 0 purchases and 11 sales selling 31,448 shares for an estimated $13,729,535.
- COLLEEN F REITAN has made 0 purchases and 16 sales selling 18,000 shares for an estimated $8,416,729.
- MICHAEL W BONNEY has made 0 purchases and 15 sales selling 22,500 shares for an estimated $8,186,716.
- PUSHKAL GARG (EVP Chief R&D) has made 0 purchases and 31 sales selling 8,810 shares for an estimated $3,991,807.
- TOLGA TANGULER (EVP, Chief Commercial Officer) has made 0 purchases and 26 sales selling 6,275 shares for an estimated $2,825,534.
- JEFFREY V. POULTON (EVP, Chief Financial Officer) has made 0 purchases and 20 sales selling 6,095 shares for an estimated $2,758,010.
- KEVIN JOSEPH FITZGERALD (CSO & EVP, Head of Research) has made 0 purchases and 20 sales selling 3,837 shares for an estimated $1,736,210.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ALNYLAM PHARMACEUTICALS Hedge Fund Activity
We have seen 409 institutional investors add shares of ALNYLAM PHARMACEUTICALS stock to their portfolio, and 279 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AQR CAPITAL MANAGEMENT LLC removed 640,095 shares (-77.3%) from their portfolio in Q2 2025, for an estimated $208,728,578
- BAILLIE GIFFORD & CO removed 625,716 shares (-17.1%) from their portfolio in Q2 2025, for an estimated $204,039,730
- CITADEL ADVISORS LLC added 596,963 shares (+14092.6%) to their portfolio in Q2 2025, for an estimated $194,663,664
- HOLOCENE ADVISORS, LP added 596,816 shares (+inf%) to their portfolio in Q2 2025, for an estimated $194,615,729
- CLEARBRIDGE INVESTMENTS, LLC added 549,322 shares (+7063.4%) to their portfolio in Q2 2025, for an estimated $179,128,410
- WELLINGTON MANAGEMENT GROUP LLP removed 535,234 shares (-20.5%) from their portfolio in Q2 2025, for an estimated $174,534,455
- MACQUARIE GROUP LTD added 527,519 shares (+726.7%) to their portfolio in Q2 2025, for an estimated $172,018,670
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ALNYLAM PHARMACEUTICALS Congressional Stock Trading
Members of Congress have traded $ALNY stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $ALNY stock by members of Congress over the last 6 months:
- REPRESENTATIVE JEFFERSON SHREVE sold up to $50,000 on 05/12.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
ALNYLAM PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $ALNY in the last several months. We have seen 15 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 10/17/2025
- JP Morgan issued a "Overweight" rating on 10/13/2025
- HC Wainwright & Co. issued a "Buy" rating on 10/10/2025
- Stifel issued a "Buy" rating on 10/06/2025
- Goldman Sachs issued a "Buy" rating on 09/16/2025
- Evercore ISI Group issued a "Outperform" rating on 09/11/2025
- BMO Capital issued a "Outperform" rating on 09/08/2025
To track analyst ratings and price targets for ALNYLAM PHARMACEUTICALS, check out Quiver Quantitative's $ALNY forecast page.
ALNYLAM PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $ALNY recently. We have seen 23 analysts offer price targets for $ALNY in the last 6 months, with a median target of $478.0.
Here are some recent targets:
- Danielle Brill from Truist Securities set a target price of $535.0 on 10/17/2025
- Jessica Fye from JP Morgan set a target price of $473.0 on 10/13/2025
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $570.0 on 10/10/2025
- Michael Ulz from Morgan Stanley set a target price of $475.0 on 10/06/2025
- Paul Matteis from Stifel set a target price of $495.0 on 10/06/2025
- Luca Issi from RBC Capital set a target price of $500.0 on 09/19/2025
- Tazeen Ahmad from B of A Securities set a target price of $520.0 on 09/17/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
